Dr. Wael E. Eid, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 435
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
SD license 5427 -
Hospitalist Physician
SD license 5427
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Elizabeth Edgewood Edgewood, KY
- St Elizabeth Florence Florence, KY
- St Elizabeth Ft Thomas Fort Thomas, KY
- St Elizabeth Dearborn Hospital Lawrenceburg, IN
- St Elizabeth Grant Williamstown, KY
Medical groups
- Summit Medical Group Inc (807 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 435
- Services billed
- 2,409
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 707 | 343 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 300 | 139 |
| New patient office or other outpatient visit, 45-59 minutes | 72 | 72 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | 28 | 28 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 28 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mounjaro (tirzepatide) Other prescribers in Covington, KY | 1,084 |
| Levothyroxine Sodium Other prescribers in Covington, KY | 772 |
| Ezetimibe Other prescribers in Covington, KY | 460 |
| Repatha Sureclick (evolocumab) Other prescribers in Covington, KY | 420 |
| Ozempic (semaglutide) Other prescribers in Covington, KY | 370 |
| Rosuvastatin Calcium Other prescribers in Covington, KY | 337 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in Covington, KY | 298 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Covington, KY | 268 |
| Novolog Flexpen (insulin aspart) Other prescribers in Covington, KY | 260 |
| Metformin Hcl Other prescribers in Covington, KY | 259 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 74 payments worth $1,833 in total to this clinician.
| Novo Nordisk Inc | $378 |
|---|---|
| Amgen Inc. | $323 |
| Sequel Med Tech, LLC | $139 |
| Kyowa Kirin, Inc. | $133 |
| Corcept Therapeutics | $125 |
| Novartis Pharmaceuticals Corporation | $122 |
| Lilly USA, LLC | $117 |
| Dexcom, Inc. | $58.98 |
| Food and Beverage | $1,768 |
|---|---|
| Education | $64.54 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Jul 13, 2025 | Education in-kind | $32.27 |
| Novo Nordisk Inc Jul 13, 2025 | Education in-kind | $32.27 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $71,912 in research payments for these studies, mostly to the institutions running them.
- A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc. - A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Eli Lilly and Company · Recruiting · NCT07269210
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.